Avidity Biosciences (RNA) Competitors $33.21 -0.71 (-2.09%) Closing price 04:00 PM EasternExtended Trading$33.34 +0.13 (+0.38%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. ITCI, GMAB, MRNA, RDY, VTRS, QGEN, ASND, BBIO, VRNA, and BPMCShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Avidity Biosciences (NASDAQ:RNA) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Does the media refer more to RNA or ITCI? In the previous week, Avidity Biosciences had 6 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 6 mentions for Avidity Biosciences and 0 mentions for Intra-Cellular Therapies. Avidity Biosciences' average media sentiment score of 0.90 beat Intra-Cellular Therapies' score of 0.29 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Overall Sentiment Avidity Biosciences Positive Intra-Cellular Therapies Neutral Is RNA or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Avidity Biosciences' net margin of -4,136.00%. Intra-Cellular Therapies' return on equity of -9.93% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,136.00% -26.96% -24.57% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do institutionals & insiders hold more shares of RNA or ITCI? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, RNA or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Avidity Biosciences. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M367.20-$322.30M-$3.00-11.07Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Which has more risk & volatility, RNA or ITCI? Avidity Biosciences has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Do analysts rate RNA or ITCI? Avidity Biosciences presently has a consensus price target of $66.35, suggesting a potential upside of 99.80%. Intra-Cellular Therapies has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryAvidity Biosciences beats Intra-Cellular Therapies on 10 of the 17 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.09B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-11.0720.7327.9019.95Price / Sales367.20321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book2.788.308.635.90Net Income-$322.30M-$55.19M$3.24B$258.42M7 Day Performance-2.44%5.07%3.22%1.94%1 Month Performance11.18%17.61%10.72%12.02%1 Year Performance-25.62%7.03%34.94%20.81% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.4518 of 5 stars$33.21-2.1%$66.35+99.8%-26.2%$4.09B$10.90M-11.07190News CoverageITCIIntra-Cellular Therapies1.0281 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0432 of 5 stars$21.46+0.3%$37.80+76.1%-18.1%$13.77B$3.12B12.192,682Gap UpMRNAModerna4.2445 of 5 stars$32.87-2.3%$46.61+41.8%-71.4%$12.71B$3.24B-3.775,800Analyst ForecastRDYDr. Reddy's Laboratories2.8255 of 5 stars$14.58+0.4%$16.95+16.3%-9.5%$12.17B$325.54B22.0827,811News CoverageEarnings ReportUpcoming EarningsVTRSViatris3.1482 of 5 stars$9.14+0.2%$10.40+13.8%-18.5%$10.73B$14.74B-2.8832,000QGENQiagen4.1569 of 5 stars$48.25+0.3%$49.40+2.4%+25.1%$10.73B$1.98B120.985,765ASNDAscendis Pharma A/S3.4995 of 5 stars$174.880.0%$223.07+27.6%+26.3%$10.69B$393.54M-27.851,017Positive NewsBBIOBridgeBio Pharma4.6041 of 5 stars$47.69+2.6%$61.20+28.3%+68.0%$9.06B$221.90M-13.51400Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.7693 of 5 stars$104.67-0.2%$109.00+4.1%+366.9%$8.91B$42.28M-52.3430High Trading VolumeBPMCBlueprint Medicines1.1533 of 5 stars$129.36+0.0%$128.25-0.9%N/A$8.35B$508.82M-52.37640Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts